NeuroTrax

NeuroTrax, founded in 2000 by a multidisciplinary team including neurologist Dr. Ely Simon, develops a computerized platform for monitoring brain wellness and cognitive function. Dr. Simon's background in both neurology and biomedical engineering informed the creation of a medical-grade, computerized cognitive assessment tool.

The company provides a medical-grade, software-as-a-service (SaaS) solution that allows clinicians and researchers to objectively measure cognitive performance across multiple domains, including memory, executive function, attention, and information processing speed. The tests, which take less than an hour, are designed to detect subtle cognitive changes that may indicate conditions like Alzheimer's disease, Mild Cognitive Impairment (MCI), stroke, or multiple sclerosis. The platform's scientific validity is supported by over 250 peer-reviewed publications.

NeuroTrax operates on a B2B and B2B2C model, serving healthcare providers such as neurologists, clinics, and hospitals, as well as researchers. For clinicians, the assessments are designed to be reimbursable in the US under various CPT codes, providing a way to enhance patient care without adding significant costs. The platform delivers detailed, patient-friendly reports and longitudinal tracking to support individualized care plans. For researchers, NeuroTrax provides reliable, repeatable assessments with data exported in analysis-ready formats.

Keywords: cognitive assessment, brain wellness, medical-grade testing, digital healthcare, neurology, cognitive domains, memory testing, executive function, information processing, clinical decision support, neuropsychological testing, medical diagnostics, SaaS, Mild Cognitive Impairment, Alzheimer's, stroke rehabilitation, multiple sclerosis, clinical research tools, reimbursable medical device